Bumpy path forecast for TG Therapeutics' Briumvi in crowded MS market

The US Food and Drug Administration’s (FDA) recent approval of TG Therapeutics’ (Nasdaq: TGTX) Briumvi (ublituximab) against relapsing forms of multiple sclerosis (MS) is welcome news for the company after suffering a major setback in 2022 when the FDA extended its review of Briumvi by three months.

However, Briumvi is unlikely to appeal to patients who are already receiving Roche (ROG: SIX) subsidiary Genentech’s Ocrevus ocrelizumab) or Novartis’ (NOVN: VX) Kesimpta (ofatumumab), says GlobalData, a data and analytics company GlobalData.

Briumvi is the third approved injectable MS treatment directed against CD20 antigen expressed on B cells, with the other therapies being Kesimpta (approved in 2020) and Ocrevus (approved in 2017). All three treatments are monoclonal antibodies.